NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results

Key Points

• NeuroPace reported quarterly earnings of ($0.26) per share, missing analysts' expectations by ($0.02), and has a significant negative return on equity of 190.84%.
• The stock has a current market cap of $299.46 million and experienced a trading increase of $0.24, reaching a price of $9.13.
• Analysts have rated the stock as a "Buy" with a consensus price target of $17.00, following multiple upgrades from firms such as JPMorgan Chase & Co. and Cantor Fitzgerald.

NeuroPace (NASDAQ:NPCE - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02), Zacks reports. NeuroPace had a negative return on equity of 190.84% and a negative net margin of 29.42%. NeuroPace updated its FY 2025 guidance to EPS.

NeuroPace Stock Performance

NPCE traded up $0.24 on Tuesday, hitting $9.13. The company had a trading volume of 244,637 shares, compared to its average volume of 275,983. The company's fifty day moving average price is $10.25 and its 200 day moving average price is $11.85. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.98. The company has a debt-to-equity ratio of 2.46, a current ratio of 6.63 and a quick ratio of 5.70. The stock has a market cap of $299.46 million, a price-to-earnings ratio of -10.87 and a beta of 1.89.

Insiders Place Their Bets

In related news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the sale, the insider directly owned 3,238,199 shares in the company, valued at approximately $51,325,454.15. The trade was a 4.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 20.50% of the company's stock.

Institutional Investors Weigh In On NeuroPace

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in NeuroPace by 44.6% in the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company's stock valued at $5,406,000 after buying an additional 149,595 shares during the period. Rhumbline Advisers raised its stake in NeuroPace by 114.5% during the second quarter. Rhumbline Advisers now owns 36,956 shares of the company's stock worth $412,000 after acquiring an additional 19,729 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after acquiring an additional 1,239 shares in the last quarter. Institutional investors own 78.83% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on NPCE shares. HC Wainwright assumed coverage on shares of NeuroPace in a research report on Wednesday, May 28th. They set a "buy" rating and a $18.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on shares of NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $17.00 price objective on shares of NeuroPace in a research note on Wednesday, May 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, NeuroPace has a consensus rating of "Buy" and a consensus price target of $17.00.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.